Login to Your Account

GTC Signs $257M Deal to Develop Antithrombin

By Catherine Hollingsworth

Tuesday, June 24, 2008
GTC Biotherapeutics Inc. and Ovation Pharmaceuticals Inc. have entered a $257 million agreement to develop and market ATryn in the U.S., a deal that includes $3 million up front, and an additional $2 million expected this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription